retatrutide phase 2 trial results Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished retatrutide phase 2 type 2

Scientists continue exploring new opportunities in this growing field

In den letzten Jahren ist der Begriff GLP-1 immer hufiger in Gesundheitsmagazinen, sozialen Medien und wissenschaftlichen Berichten zu finden

Oral S-Adenosylmethionine in depression: A randomized, double-blind, placebo-controlled trial

9 Intervention strategies with direct clinical translation potential While drug repurposing based on neurodegenerative disease mechanisms is a core focus of this research, several non-pharmacological or clinically applied interventions also show potential for tinnitus management by modulating these shared pathological pathways

Standard automated perimetry (SAP) revealed an inferior altitudinal visual field (VF) defect with a mean deviation (MD) of -13.8 dB OD (Fig

For those who have already lost a significant amount of weight or have a lower body fat percentage, a 4mm or 5mm needle might be preferred to avoid hitting the muscle